HCA Healthcare, Inc. (HCA) — Fair Value Analysis
Base-case fair value (P50): $533.83 · Current price: $404.68 · Verdict: Undervalued
The Verdict on HCA
Monte Carlo simulations strongly indicate that HCA Healthcare (HCA) is currently undervalued, definitively addressing any concerns about it being overvalued. Our analysis establishes a median fair value (P50) of $533.83, which stands significantly above its current trading price of $404.68. This substantial discrepancy points to a potential +31.9%, suggesting the market has yet to fully price in HCA's intrinsic worth within the Healthcare sector. The rigorous simulation, modeling thousands of diverse forward-looking scenarios for HCA, consistently places its robust valuation well above its prevailing market capitalization.
How HCA stacks up against Healthcare
HCA maintains an average quality tier for its operational and financial health when benchmarked against its Healthcare sector peers. This assessment, derived from a comprehensive review, highlights HCA's stable, albeit not top-tier, standing. Crucially, even with an average quality profile, the considerable gap between HCA’s $404.68 and its calculated $533.83 fair value, representing +31.9%, underscores a compelling valuation thesis. It suggests that the market may be overlooking the inherent value potential of a fundamentally sound company like HCA, even when its quality tier is not exceptional.
What this means for investors
For investors evaluating HCA, the projected +31.9% from the current trading price of $404.68 to the $533.83 fair value of $533.83 offers a robust directional indicator. While a complete investment thesis requires understanding the full spectrum of simulated outcomes, including various downside scenarios and bull case potential, the baseline median fair value firmly positions HCA as undervalued, not overvalued. FairCurve provides the comprehensive framework to explore these nuances. To access the full bear/bull distribution and track HCA's dynamic fair value as new fundamentals are released, sign up for a free FairCurve account today.
Frequently Asked Questions
Is HCA overvalued or undervalued right now?
HCA is currently undervalued. Our Monte Carlo simulations show a median fair value (P50) of $533.83 compared to its current market price of $404.68.
What is the bear case and bull case for HCA?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, alongside the probability of achieving upside, is exclusively available with a free FairCurve account.
How does FairCurve calculate HCA's fair value?
FairCurve calculates HCA's fair value using sophisticated Monte Carlo simulations that model thousands of forward scenarios to generate a comprehensive probability distribution of potential outcomes.
How can I track HCA's fair value as it changes?
You can add HCA to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts whenever new earnings reports or significant fundamental data are released.